Ted Myles Joins Cellarity as Chief Executive Officer
Cellarity has appointed Ted Myles as its new Chief Executive Officer and CEO-Partner at Flagship Pioneering. Myles brings extensive biopharma leadership experience, previously serving as CFO and COO of Scholar Rock where he raised over $1 billion and led the company through a successful Phase 3 study. His prior roles include executive positions at AMAG Pharmaceuticals, Ocata Therapeutics, and PrimeraDx.
The appointment comes as Cellarity prepares for its first clinical study in 2025. The company leverages an AI/ML-enabled platform for drug discovery, focusing on understanding dysregulated pathways in diseased human cells. Their lead program, CLY-124, is a potential first-in-class small molecule for sickle cell disease treatment, targeting fetal hemoglobin induction through a novel mechanism, with clinical development expected to begin in mid-2025.
Cellarity ha nominato Ted Myles come nuovo Amministratore Delegato e CEO-Partner di Flagship Pioneering. Myles vanta una vasta esperienza nella leadership nel settore biofarmaceutico, avendo ricoperto in precedenza i ruoli di CFO e COO presso Scholar Rock, dove ha raccolto oltre 1 miliardo di dollari e guidato l'azienda attraverso uno studio di Fase 3 di successo. Tra le sue esperienze precedenti figurano posizioni dirigenziali presso AMAG Pharmaceuticals, Ocata Therapeutics e PrimeraDx.
La nomina avviene mentre Cellarity si prepara al suo primo studio clinico previsto per il 2025. L'azienda utilizza una piattaforma abilitata da AI/ML per la scoperta di farmaci, concentrandosi sulla comprensione dei percorsi disfunzionali nelle cellule umane malate. Il loro programma principale, CLY-124, è una potenziale molecola di prima classe per il trattamento dell'anemia falciforme, che mira all'induzione dell'emoglobina fetale tramite un meccanismo innovativo, con lo sviluppo clinico previsto per metà 2025.
Cellarity ha designado a Ted Myles como su nuevo Director Ejecutivo y CEO-Partner en Flagship Pioneering. Myles aporta una amplia experiencia en liderazgo biofarmacéutico, habiendo sido anteriormente CFO y COO de Scholar Rock, donde recaudó más de mil millones de dólares y lideró la empresa durante un exitoso estudio de Fase 3. Sus roles previos incluyen cargos ejecutivos en AMAG Pharmaceuticals, Ocata Therapeutics y PrimeraDx.
El nombramiento se produce mientras Cellarity se prepara para su primer estudio clínico en 2025. La compañía utiliza una plataforma habilitada por IA/ML para el descubrimiento de fármacos, enfocándose en entender las vías desreguladas en células humanas enfermas. Su programa principal, CLY-124, es una posible molécula de primera clase para el tratamiento de la enfermedad de células falciformes, que apunta a la inducción de hemoglobina fetal mediante un mecanismo novedoso, con el desarrollo clínico esperado para mediados de 2025.
Cellarity는 Ted Myles를 새로운 최고경영자(CEO) 및 Flagship Pioneering의 CEO-파트너로 임명했습니다. Myles는 Scholar Rock에서 CFO 및 COO로 재직하며 10억 달러 이상을 조달하고 성공적인 3상 임상시험을 이끈 풍부한 바이오제약 리더십 경험을 가지고 있습니다. 이전에는 AMAG Pharmaceuticals, Ocata Therapeutics, PrimeraDx에서 임원직을 역임했습니다.
이번 임명은 Cellarity가 2025년 첫 임상시험을 준비하는 시점에 이루어졌습니다. 회사는 AI/ML 기반 플랫폼을 활용해 질병이 있는 인간 세포 내 조절되지 않은 경로를 이해하는 데 집중하여 신약을 개발하고 있습니다. 주력 프로그램인 CLY-124는 새로운 기전을 통해 태아 헤모글로빈 유도를 목표로 하는 겸상적혈구병 치료를 위한 잠재적 퍼스트인클래스 소분자이며, 2025년 중반에 임상 개발이 시작될 예정입니다.
Cellarity a nommé Ted Myles en tant que nouveau Directeur Général et CEO-Partner chez Flagship Pioneering. Myles apporte une vaste expérience en leadership dans le secteur biopharmaceutique, ayant précédemment occupé les postes de CFO et COO chez Scholar Rock, où il a levé plus d'un milliard de dollars et conduit l'entreprise à travers une étude de Phase 3 réussie. Ses expériences antérieures incluent des postes exécutifs chez AMAG Pharmaceuticals, Ocata Therapeutics et PrimeraDx.
Cette nomination intervient alors que Cellarity se prépare à son premier essai clinique en 2025. L'entreprise utilise une plateforme propulsée par l'IA/ML pour la découverte de médicaments, se concentrant sur la compréhension des voies dysrégulées dans les cellules humaines malades. Leur programme principal, CLY-124, est une petite molécule potentiellement de première classe pour le traitement de la drépanocytose, ciblant l'induction de l'hémoglobine fœtale via un mécanisme novateur, avec un développement clinique attendu pour la mi-2025.
Cellarity hat Ted Myles zum neuen Chief Executive Officer und CEO-Partner bei Flagship Pioneering ernannt. Myles bringt umfangreiche Führungserfahrung in der Biopharma-Branche mit, zuvor war er CFO und COO bei Scholar Rock, wo er über 1 Milliarde Dollar einwarb und das Unternehmen durch eine erfolgreiche Phase-3-Studie führte. Zuvor bekleidete er Führungspositionen bei AMAG Pharmaceuticals, Ocata Therapeutics und PrimeraDx.
Die Ernennung erfolgt, während Cellarity sich auf seine erste klinische Studie im Jahr 2025 vorbereitet. Das Unternehmen nutzt eine KI/ML-gestützte Plattform zur Wirkstoffentdeckung, die sich auf das Verständnis dysregulierter Signalwege in erkrankten menschlichen Zellen konzentriert. Ihr Hauptprogramm, CLY-124, ist ein potenzielles First-in-Class-Kleinmolekül zur Behandlung der Sichelzellanämie, das die Induktion von fetalem Hämoglobin durch einen neuartigen Mechanismus anstrebt, mit einem klinischen Entwicklungsstart Mitte 2025.
- Appointment of experienced CEO with track record of raising capital ($1B+ at Scholar Rock)
- Company's first clinical trial anticipated in 2025
- Lead program CLY-124 advancing towards clinical development
- Strong AI/ML platform capabilities in drug discovery
- None.
Insights
CEO appointment of experienced Ted Myles positions Cellarity for clinical transition as lead program CLY-124 approaches trials in mid-2025.
Ted Myles' appointment as Cellarity CEO comes at a critical inflection point as the company prepares for its first clinical trial. Myles brings substantial operational experience from his previous executive roles at Scholar Rock, where he raised over
Particularly notable is Cellarity's AI-powered drug discovery platform, which utilizes single-cell transcriptomics to identify novel targets. Their lead program, CLY-124, targets sickle cell disease through a first-in-class approach inducing fetal hemoglobin via a novel mechanism. With clinical development slated for mid-2025, Myles arrives precisely when experienced leadership in clinical execution becomes essential.
The timing of this leadership transition signals Cellarity's evolution from platform development to clinical-stage company. Myles' dual appointment as CEO-Partner at Flagship Pioneering also suggests strong financial backing will continue, as Flagship appears committed to Cellarity's platform expansion into new disease areas. His experience raising substantial capital will be crucial as the company transitions from preclinical to clinical operations, typically requiring significantly increased funding.
Myles, a Biopharma Industry Veteran, Will Also Join Flagship Pioneering as a CEO-Partner
Myles is a seasoned biopharma leader with deep experience and a track record for building clinical and commercial-stage companies. Previously, he was Chief Financial Officer and Chief Operating Officer of Scholar Rock where he led the company through its evolution from early development-stage through a successful Phase 3 registrational study and raised more than
"As Cellarity approaches a significant inflection point with its first anticipated clinical study this year, Ted's executive leadership experience across the development spectrum will be essential to delivering on and expanding the value of Cellarity's scientific platform and product development strategy," said Stephen Berenson, Chairman of the Cellarity Board and Managing Partner Emeritus of Flagship Pioneering. "On behalf of the entire Board, we welcome Ted and look forward to a fruitful partnership."
"Cellarity is a powerhouse of AI-powered biotechnology as it brings data, biology, and chemistry together in truly distinctive ways. I am impressed by the strength of its end-to-end platform and the novelty of the programs it is producing for important indications, and I'm excited to lead such a strong team as we move into the clinical stage of program development and extend the platform into new disease areas," said Myles. "I look forward to partnering with leaders across Cellarity as we work to bring novel, world class medicines to patients."
"At Flagship, we are enthusiastic about Cellarity's accelerated trajectory fueled by an increasingly mature platform capable of producing completely novel medicines that target complex disease biology in an entirely unique way," said Noubar Afeyan, Ph.D., Co-founder of Cellarity and Founder and CEO of Flagship Pioneering. "We congratulate the company on Ted's appointment – he is the right leader to take the helm given his executive acumen and inspired leadership, and we know that he will be a valued voice across the Flagship ecosystem."
Cellarity's drug discovery approach starts with the understanding of dysregulated pathways in diseased human cells and reveals novel targets and medicines to generate first-in-class approaches with higher likelihood of success in the clinic. Through its industry-leading AI/ML-enabled platform and using single-cell transcriptomics, the company is uncovering novel druggable biology for complex diseases and advancing a rich and highly differentiated pipeline of small molecule programs. The company's lead program, CLY-124, is a potential first-in-class small molecule developed for the treatment of sickle cell disease. CLY-124 induces fetal hemoglobin via a novel target identified using Cellarity's platform and is expected to enter clinical development in mid-2025.
About Cellarity
Founded by Flagship Pioneering in 2019, Cellarity is redefining how medicines are created by starting with an understanding of the cellular dysfunction that drives disease. By shifting the drug discovery paradigm, Cellarity unravels biological complexity to develop therapies beyond the reach of traditional approaches. The company's platform combines proprietary AI/ML models with over 45 million single-cell transcriptomes, enabling the discovery of novel, actionable biology and the design of non-intuitive small molecule drug candidates across a broad range of diseases. Cellarity's lead program is a small molecule for sickle cell disease, with additional programs in hematology and immunology, and an active collaboration with Novo Nordisk targeting metabolic dysfunction-associated steatohepatitis (MASH). For more information, visit www.cellarity.com.
About Flagship Pioneering
Flagship Pioneering invents and builds bioplatform companies, each with the potential for multiple products that transform human health or sustainability. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures, resulting in more than
Media Contacts:
press@flagshippioneering.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ted-myles-joins-cellarity-as-chief-executive-officer-302451967.html
SOURCE Flagship Pioneering
FAQ
Who is Ted Myles and what is his role at Cellarity?
What is Cellarity's lead drug program and when will clinical trials begin?
What is Cellarity's approach to drug discovery?
What is Ted Myles' previous experience in the biotech industry?
